Suppression of neuroinflammation by the dopamine receptor D2 via alphaB-crystallin by Zhou, Jiawei
LECTURE PRESENTATION Open Access
Suppression of neuroinflammation by the
dopamine receptor D2 via alphaB-crystallin
Jiawei Zhou
From 2011 International Conference on Molecular Neurodegeneration
Shanghai, China. 22-24 September 2011
Chronic neuroinflammation is a common feature of aging
brain and some neurodegenerative diseases, including
Parkinson’s disease. However, the molecular mechanisms
underlying regulation of innate immunity in the central
nervous system remain elusive. Here we show that dopa-
mine receptor D2 (Drd2), known as a critical component
for dopamine neurotransmission and a susceptibility gene
for Parkinson’s disease, modulates innate immunity
through its downstream target protein astrocytic alphaB-
crystallin (Cryab). We demonstrate that knockout mice
lacking Drd2 showed remarkable inflammatory response
in multiple CNS regions and increased vulnerability of
nigral dopaminergic neurons to MPTP-induced neurotoxi-
city. Drd2—/— astrocytes became hyper- responsive to
immune stimuli with dramatic reduction in levels of
Cryab. Gain- or loss-of-function studies showed that
Cryab is critical for Drd2-mediated modulation of innate
immune response in astrocytes.I n t e r e s t i n g l y ,a b e r r a n t
expression of Cryab in reactive astrocytes was found in the
ventral mesencephalon of patients with Parkinson’sd i s -
ease. Furthermore, treatment of wild-type mice with a
selective Drd2 agonist increased resistance of the nigral
dopaminergic neurons to neurotoxin via partial suppres-
sion of inflammation. Altogether, these data suggest that
Drd2 / Cryab pathway in astrocytes is crucial for repres-
sion of neuroinflammation and thus could be therapeuti-
cally useful for treatment of Parkinson’s disease.
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